C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on September 5, 2023, regarding events occurring between August 30, 2023, and September 5, 2023. The filing addresses significant changes in the Company's executive leadership, specifically within the finance and accounting functions.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Lauren White resigned as Chief Financial Officer, Treasurer, Principal Financial Officer, and Principal Accounting Officer, effective September 15, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or accounting practices.
- Appointment of CFO: Kendra Adams was appointed as Chief Financial Officer, Treasurer, and Principal Financial Officer, effective September 18, 2023. She previously served as Senior Vice President, Communications and Investor Relations.
- Appointment of Chief Accounting Officer: Mark Mossler was appointed as Chief Accounting Officer and Principal Accounting Officer, effective September 18, 2023. He previously served as Vice President, Corporate Controller.
Compensation and Outlook
The filing details the compensation packages for the newly appointed officers:
- Kendra Adams (CFO): Annual base salary of $450,000; eligible for an annual performance bonus of up to 40% of base salary. Equity awards include options to purchase 111,000 shares (vesting 25% at one year, remainder quarterly over three years) and 25,000 restricted stock units (vesting annually over four years).
- Mark Mossler (CAO): Annual base salary of $315,000; eligible for an annual performance bonus of up to 30% of base salary.
Both officers are parties to indemnification agreements. The filing does not provide specific guidance, outlook, or risk factors beyond the standard disclosure of leadership transitions.
Key Facts for Investor Verification
- Verify the effective dates of the leadership transition (September 15 and September 18, 2023) to ensure continuity in financial reporting.
- Review the equity grant terms for Kendra Adams, specifically the exercise price determination based on the Nasdaq closing price on the commencement date.
- Confirm that the resignation of the previous CFO was not related to any undisclosed accounting irregularities, as stated in the filing.
- Monitor future filings for the impact of these leadership changes on the Company's financial reporting and investor relations strategy.